1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one

C21H30N6O2 — CID 137439704

IUPAC1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one
SMILESCC(C)C(=O)N1CCC(c2noc(N3CCc4nn(C5CCC5)cc4C3)n2)CC1
InChIInChI=1S/C21H30N6O2/c1-14(2)20(28)25-9-6-15(7-10-25)19-22-21(29-24-19)26-11-8-18-16(12-26)13-27(23-18)17-4-3-5-17/h13-15,17H,3-12H2,1-2H3
InChIKeyKVRBYFAKYWTDKV-UHFFFAOYSA-N
MW398.51 g/mol
LogP2.92
Rot. Bonds4

About 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one

1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one (PubChem CID 137439704) has the molecular formula C21H30N6O2 and a molecular weight of 398.51 g/mol. Its IUPAC name is 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one.

Molecular Properties

Compound Name1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one
PubChem CID137439704
Molecular FormulaC21H30N6O2
Molecular Weight398.51 g/mol
Exact Mass398.24
IUPAC Name1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one
SMILESCC(C)C(=O)N1CCC(c2noc(N3CCc4nn(C5CCC5)cc4C3)n2)CC1
InChIInChI=1S/C21H30N6O2/c1-14(2)20(28)25-9-6-15(7-10-25)19-22-21(29-24-19)26-11-8-18-16(12-26)13-27(23-18)17-4-3-5-17/h13-15,17H,3-12H2,1-2H3
InChIKeyKVRBYFAKYWTDKV-UHFFFAOYSA-N
XLogP2.92
TPSA80.29 Ų
H-Bond Donors
H-Bond Acceptors7
Rotatable Bonds4
Heavy Atoms29
Complexity

Lipinski Rule of Five

Passes Rule of Five

RuleValue
MW ≤ 500398.51
LogP ≤ 52.92
H-Bond Donors ≤ 50
H-Bond Acceptors ≤ 107

Analyze 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Frequently Asked Questions

What is the IUPAC name of 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one?
The IUPAC name of 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one (CID 137439704) is 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one.
What is the SMILES notation for 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one?
The canonical SMILES for 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one is CC(C)C(=O)N1CCC(c2noc(N3CCc4nn(C5CCC5)cc4C3)n2)CC1.
What is the InChIKey of 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one?
The InChIKey is KVRBYFAKYWTDKV-UHFFFAOYSA-N. The full InChI is InChI=1S/C21H30N6O2/c1-14(2)20(28)25-9-6-15(7-10-25)19-22-21(29-24-19)26-11-8-18-16(12-26)13-27(23-18)17-4-3-5-17/h13-15,17H,3-12H2,1-2H3.
What are the key properties of 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one?
1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one has a molecular weight of 398.51 g/mol, XLogP of 2.92, 4 rotatable bonds, 0 hydrogen bond donors, and 7 hydrogen bond acceptors.
Where does this data come from?
All data for 1-[4-[5-(2-cyclobutyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1,2,4-oxadiazol-3-yl]piperidin-1-yl]-2-methylpropan-1-one is sourced from PubChem (CID 137439704), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).